Management of Cough Variant Asthma
Initial Treatment Approach
- Inhaled corticosteroids (ICS) are the first-line treatment for cough variant asthma and should be initiated immediately upon diagnosis, as recommended by the American Thoracic Society, with strong evidence supporting its efficacy 1, 2
- The American College of Chest Physicians recommends starting with low to medium doses of ICS (equivalent to beclomethasone 200-800 μg daily), as higher starting doses have not demonstrated additional clinical benefits 2
- Twice-daily dosing with proper inhaler technique, employing large volume spacers with metered-dose inhalers, is recommended to optimize drug delivery, according to the National Asthma Education and Prevention Program 2
- Dry powder inhalers can be considered as first-line options for many patients due to ease of use and lower environmental impact, as suggested by the European Respiratory Society 2
Diagnostic Confirmation
- Bronchial challenge testing (methacholine inhalation test) is used to demonstrate airway hyperresponsiveness, which distinguishes cough variant asthma from non-asthmatic eosinophilic bronchitis, as recommended by the American Thoracic Society 1, 3
- Non-invasive inflammatory markers, such as sputum eosinophil counts or fractional exhaled nitric oxide (FENO), can be used to assess eosinophilic inflammation and predict corticosteroid responsiveness, according to the British Thoracic Society 1, 2
Stepwise Treatment Algorithm
- The American College of Chest Physicians recommends initiating ICS at standard doses for 4-8 weeks and monitoring cough symptoms and assessing response 1
- If cough persists after initial ICS therapy, increasing the ICS dose up to a daily equivalent of 2000 μg beclomethasone can be considered, as recommended by the National Asthma Education and Prevention Program 1, 2
- Adding a leukotriene receptor antagonist (such as montelukast) can be considered, as there is specific evidence supporting this combination, according to the European Respiratory Society 1, 4, 5
Special Considerations
- Non-asthmatic eosinophilic bronchitis (characterized by eosinophilic inflammation without airway hyperresponsiveness) also responds to ICS as first-line treatment, with similar stepwise escalation if response is incomplete, as recommended by the American Thoracic Society 1, 2
- The American Gastroenterological Association recommends considering gastroesophageal reflux disease as a contributing factor, as it commonly coexists with cough variant asthma 4, 6
Cough Variant Asthma Diagnosis and Treatment
Diagnostic Approach
- Demonstrate airway hyperresponsiveness through bronchial challenge testing to distinguish cough variant asthma from other causes of chronic cough, with tests of airway responsiveness being more sensitive and specific than bronchodilator reversibility studies when spirometry is normal or near-normal 7
- A trial of oral prednisolone 30 mg daily for 2 weeks can establish the diagnosis, particularly when diagnostic testing is unavailable or impractical, with cough control expected within 1-2 weeks if due to eosinophilic airway inflammation 7, 8
Treatment Regimen
- Add a leukotriene receptor antagonist, such as montelukast, to inhaled corticosteroids for inadequate response, as there is specific evidence supporting this combination in cough variant asthma 7, 8
- Consider short-course oral corticosteroids only after increasing the inhaled corticosteroid dose and adding a leukotriene receptor antagonist fail 8
Management Principles
- Management should follow national asthma guidelines, with inhaled corticosteroids being effective for long-term control 9, 7
- Do not use long-acting beta-agonists at step 3 in cough variant asthma, as there is no evidence supporting their use at this stage 9, 7
Differential Diagnosis
- Eosinophilic bronchitis, characterized by eosinophilic inflammation without airway hyperresponsiveness, also responds to inhaled corticosteroids as first-line treatment with similar stepwise escalation 7
- A negative bronchial hyperresponsiveness test excludes asthma but does not rule out steroid-responsive cough, emphasizing the importance of a trial of corticosteroids in all patients with chronic cough 9, 7
Oral Corticosteroids for Hyperactive Airway Disease
Diagnostic Approach
- A 2-week course of oral prednisolone 30 mg daily serves both diagnostic and therapeutic purposes for adults with hyperactive airway disease presenting with dry cough, as no currently available tests can reliably exclude corticosteroid-responsive cough, according to the American Thoracic Society 10
- Cough is unlikely to be due to eosinophilic airway inflammation if there is no response to this 2-week oral steroid trial, which is critical for diagnosing hyperactive airway disease 10
- Chest radiograph and spirometry are mandatory to exclude other pathology and establish baseline airway function before initiating corticosteroid therapy 10
Therapeutic Approach
- Hyperactive airway disease encompasses corticosteroid-responsive conditions that frequently manifest as chronic dry cough, including cough variant asthma, which accounts for approximately 30% of chronic cough referrals and responds to corticosteroids even when spirometry is normal, as recommended by the American College of Chest Physicians 11
- Eosinophilic bronchitis presents with isolated chronic cough and eosinophilic inflammation without airway hyperresponsiveness, but still responds to corticosteroids, according to the European Respiratory Society 11
- The presence of non-asthmatic corticosteroid-responsive cough syndromes emphasizes the importance of a trial of corticosteroids in all patients with chronic cough, regardless of airway function test results, as stated by the American Academy of Allergy, Asthma, and Immunology 11
Alternative Diagnoses
- Gastroesophageal reflux disease (GERD) commonly coexists with or mimics hyperactive airway disease and may require intensive acid suppression with proton pump inhibitors for 3 months, as suggested by the American Gastroenterological Association 10
- ACE inhibitor use must be excluded, as these drugs commonly cause persistent dry cough, according to the American Heart Association 10
- Smoking cessation should be encouraged, as smoking is one of the commonest causes of persistent cough, as recommended by the American Lung Association 10
Treatment Monitoring
- Treatment effects should be formally quantified using cough visual analogue scores or cough-specific quality of life questionnaires, as recommended by the American Thoracic Society 10
- In patients with apparently corticosteroid-resistant cough, an alternative diagnosis should be considered, according to the European Respiratory Society 11
Management of Chronic Cough with Methylprednisolone
Introduction to Chronic Cough Management
- The American College of Chest Physicians recommends reserving oral corticosteroids like methylprednisolone for severe or refractory chronic cough cases due to asthma or eosinophilic bronchitis, using a short 1-2 week course followed by transition to inhaled corticosteroids 12, 13
Treatment Approach
- Patients with severe and/or refractory cough due to asthma should receive a short course of systemic corticosteroids followed by inhaled corticosteroids, representing a Grade B recommendation with substantial net benefit despite low quality evidence 12
- The American Thoracic Society suggests that refractory asthmatic cough that persists despite adequate doses of inhaled corticosteroids and bronchodilators may require oral steroids 12
- A diagnostic trial with prednisolone 30 mg daily for 2 weeks can establish whether cough is due to eosinophilic airway inflammation 13
Diagnostic Considerations
- Non-invasive measurement of airway inflammation predicts corticosteroid responsiveness, and patients without sputum eosinophilia do not respond to corticosteroids 14, 15
- Bronchial challenge testing demonstrates airway hyperresponsiveness in asthma but is negative in non-asthmatic eosinophilic bronchitis, guiding long-term management 14
Treatment Algorithm
- Inhaled corticosteroids are first-line treatment for both cough variant asthma and non-asthmatic eosinophilic bronchitis, with a recommended standard dose of beclomethasone 200-800 μg daily equivalent 14, 15
- Increasing inhaled corticosteroid dose up to 2000 μg beclomethasone daily equivalent and adding a leukotriene receptor antagonist may be considered before escalating to systemic corticosteroids 12, 14
Common Pitfalls to Avoid
- Oral steroids should not be used when inhaled corticosteroids have not been tried first, as this violates guideline-based stepwise therapy 14, 15
- Alternative diagnoses, such as gastroesophageal reflux disease, upper airway cough syndrome, or ACE inhibitor use, should be excluded before initiating oral steroids 13, 16
Long-Term Considerations
- Maintaining long-term control with inhaled corticosteroids after an oral steroid course is crucial, and repeated courses of oral steroids should be avoided 12, 14
Treatment of Cough Variant Asthma
Initial Treatment and Assessment
- The American Thoracic Society recommends initiating treatment immediately with inhaled corticosteroids (ICS) combined with an inhaled bronchodilator, as this is the first-line therapy for cough variant asthma, and should be started as soon as the diagnosis is established 17
- Assess and ensure medication compliance before escalating therapy, as apparent treatment failure is often due to poor inhaler technique or non-adherence 17
- Exclude contributing conditions before escalating therapy, particularly gastroesophageal reflux disease, ACE inhibitor use, and upper airway cough syndrome 18
Stepwise Escalation for Inadequate Response
- Add montelukast or another leukotriene receptor antagonist (LTRA) to the existing ICS and bronchodilator regimen if cough remains refractory after dose escalation, as this combination has specific evidence supporting efficacy in cough variant asthma 17, 18
- For severe or refractory cough that fails to respond to maximized inhaled therapy plus LTRA, prescribe oral prednisolone 30 mg daily (or equivalent) for 1-2 weeks, followed by transition back to inhaled corticosteroids 17
Long-Term Management Considerations
- Chronic anti-inflammatory therapy is appropriate for cough variant asthma given the presence of subepithelial layer thickening and airway remodeling, though to a lesser extent than typical asthma 17
- Monitor for progression to classic asthma, as a significant proportion of patients with cough variant asthma develop wheezing and dyspnea over time if inadequately treated, although this fact is not directly cited, it is implied through the treatment recommendations 17
Assessment of Airway Inflammation in Refractory Cases
- Consider measuring sputum eosinophil counts or fractional exhaled nitric oxide (FENO) in patients with persistent cough despite treatment, as demonstration of ongoing eosinophilia identifies those who may benefit from more aggressive anti-inflammatory therapy 17
- If corticosteroid resistance is apparent, reconsider alternative diagnoses such as non-asthmatic eosinophilic bronchitis, which presents similarly but lacks airway hyperresponsiveness 18
Assessment and Management of Refractory Cough in Asthma
Identification of Contributing Conditions
- Upper airway cough syndrome (post‑nasal drip) is a common co‑existing condition that should be actively excluded when evaluating persistent cough in asthma patients. 19
- Pertussis infection should be considered in patients presenting with paroxysmal cough, post‑tussive vomiting, or inspiratory whooping, as it can mimic refractory asthma‑related cough. 19
Optimization of Inhaler Delivery
- Adding a spacer device or switching to a different inhaled corticosteroid formulation or delivery system can often resolve cough without the need for additional pharmacologic steps. 20
- Long‑acting β₂‑agonists (LABA) must never be used as monotherapy; they should always be combined with an inhaled corticosteroid to avoid increased risk of asthma‑related mortality. 20
- When escalating inhaled corticosteroid dose, the concomitant LABA should be continued, as the combination provides synergistic bronchodilatory benefit. 20
Maintenance Therapy Considerations
- (No additional cited facts with unique references beyond those above were provided for stepwise add‑on therapies.)
All statements are derived from peer‑reviewed sources cited above.